TG Therapeutics, Inc. Financials

TG Therapeutics generated about $800 million in revenue over the trailing twelve months. Revenue has grown at roughly 426.7% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Yes, TG Therapeutics reported about $441 million in net income over the trailing twelve months, a net profit margin of roughly 55.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

TG Therapeutics runs a gross margin of about 82.4%, an operating margin of about 17.1%, a net margin of about 55.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

TG Therapeutics's revenue has compounded at roughly 426.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside TGTX's margins and free cash flow. This is analysis from SEC filings, not investment advice.